如何制作指南（NCCN，ESMO......）

NCCN NSCLC guidelines panel

• 38 members from across NCCN institutions
• Multidisciplinary group:
  

• Surgeon
• Medical Oncologist
• Pulmonologist
• Interventional Radiologist
• Pathologist
• Molecular pathologist
  

• Patient representative
  

How are changes made in the guidelines?

• Yearly review by all NCCN institutions
• External submissions - patient advocates, organizations, industry, and/or payers
• Annual in-person meeting
  

• Interim updates
  

• all new FDA drug approvals
• expanded FDA drug indications
• publications/presentations that impact to clinical practice
  

NCCN Categories of Evidence and Consensus

• clinical evidence available
• degree of consensus within the panel
  

• Category 1
  

Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate

• Category 2A
  

Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate

• Category 2B
  

Based upon lower-level evidence, there is NCCN consensus (≥50% but <85% support of the Panel) that the intervention is appropriate

• Category 3
  

Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate

Key standard operating procedures (SOPs)

Clinical Practice Guidelines should follow the following thematic sections*

• Incidence and epidemiology
• Diagnosis, pathology and molecular biology
• Staging and risk assessment
• Management of local and locoregional disease
• Management of advanced and metastatic disease
• Follow-up, long-term implications and survivorship
  

Templates are provided to the authors for the manuscript, supplementary material and algorithms

• They are pre-formatted according to the journal requirements and ESMO SOPs
  

Recommendations for each section must be summarised in bullet point list at end of each section

• All recommendations must have a LoE and GoR
  

Guideline should focus on therapeutic recommendations

• Should be clear and easy to understand and interpret for practicing clinicians (including non-specialists)
• Extensive discussion of clinically un-actionable research might not be necessary
  

Management/therapeutic algorithms must be provided

• The list of recommendations and the algorithms should be aligned
  

Interactive CPG algorithms and recommendations
Fully accessible to mobile smaller screens
With direct links to references and MCBS Scorecards

Take a look at: https://www.esmo.org/living-guidelines



Based on the Living Guidelines:
Development of a slide set for each Living Guideline, updated when the Living Guideline is updated
Downloadable as ppt slides from the Living Guideline landing page
Individual slides can be extracted for use in presentations (cannot be edited)